Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2020 Dec 23

PMID 33352973

Citations 4

Authors

Majdi N Al-Hasan

Affiliations

Soon will be listed here.

Abstract

The age- and sex-adjusted incidence rate of Gram-negative bloodstream infection (GN-BSI) is 84 [...].

Citing Articles

The epidemiology of gram-negative bacteremia in Lebanon: a study in four hospitals.

Nasr J, Abdessamad H, Mina J, Haykal T, Jamil Y, Abboud E Ann Clin Microbiol Antimicrob. 2024; 23(1):90.

PMID: 39385237 PMC: 11465513. DOI: 10.1186/s12941-024-00740-0.

Adult acute leukemia patients with gram-negative bacteria bloodstream infection: Risk factors and outcomes of antibiotic-resistant bacteria.

Wang J, Mu M, Zhu J, Yang J, Tao Y, Chen Y Ann Hematol. 2024; 103(10):4021-4031.

PMID: 38958702 PMC: 11512823. DOI: 10.1007/s00277-024-05866-x.

Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.

Corona A, De Santis V, Agarossi A, Prete A, Cattaneo D, Tomasini G Antibiotics (Basel). 2023; 12(8).

PMID: 37627683 PMC: 10451333. DOI: 10.3390/antibiotics12081262.

Bacteriological Profile and Antimicrobial Susceptibility Patterns of Gram-Negative Bloodstream Infection and Risk Factors Associated with Mortality and Drug Resistance: A Retrospective Study from Shanxi, China.

Shi N, Kang J, Wang S, Song Y, Yin D, Li X Infect Drug Resist. 2022; 15:3561-3578.

PMID: 35833010 PMC: 9271686. DOI: 10.2147/IDR.S370326.

References

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

Shealy S, Brigmon M, Justo J, Bookstaver P, Kohn J, Al-Hasan M . Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates. Antibiotics (Basel). 2020; 9(4). PMC: 7235854. DOI: 10.3390/antibiotics9040189. View

Cain S, Kohn J, Bookstaver P, Albrecht H, Al-Hasan M . Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis. Antimicrob Agents Chemother. 2014; 59(1):245-50. PMC: 4291357. DOI: 10.1128/AAC.03935-14. View

Brigmon M, Bookstaver P, Kohn J, Albrecht H, Al-Hasan M . Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization. Clin Microbiol Infect. 2015; 21(9):843-9. DOI: 10.1016/j.cmi.2015.05.013. View

Suzuki H, Perencevich E, Livorsi D, Alexander B, Beck B, Richardson K . Attributable mortality due to fluoroquinolone and extended-spectrum cephalosporin resistance in hospital-onset Escherichia coli and Klebsiella spp bacteremia: A matched cohort study in 129 Veterans Health Administration medical centers. Infect Control Hosp Epidemiol. 2019; 40(8):928-931. DOI: 10.1017/ice.2019.155. View

Fokam D, Dickson K, Kamali K, Holbein B, Colp P, Stueck A . Iron Chelation in Murine Models of Systemic Inflammation Induced by Gram-Positive and Gram-Negative Toxins. Antibiotics (Basel). 2020; 9(6). PMC: 7345558. DOI: 10.3390/antibiotics9060283. View

Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K . Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. PMC: 6812437. DOI: 10.1164/rccm.201908-1581ST. View

Al-Hasan M . Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target. Clin Infect Dis. 2020; 72(12):2121-2123. DOI: 10.1093/cid/ciaa384. View

Battle S, Bookstaver P, Justo J, Kohn J, Albrecht H, Al-Hasan M . Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis. J Antimicrob Chemother. 2016; 72(1):299-304. DOI: 10.1093/jac/dkw402. View

10.

Al-Hasan M, Juhn Y, Bang D, Yang H, Baddour L . External validation of bloodstream infection mortality risk score in a population-based cohort. Clin Microbiol Infect. 2014; 20(9):886-91. PMC: 4254722. DOI: 10.1111/1469-0691.12607. View

11.

Suzuki H, Perencevich E, Nair R, Livorsi D, Goto M . Excess Length of Acute Inpatient Stay Attributable to Acquisition of Hospital-Onset Gram-Negative Bloodstream Infection with and without Antibiotic Resistance: A Multistate Model Analysis. Antibiotics (Basel). 2020; 9(2). PMC: 7168210. DOI: 10.3390/antibiotics9020096. View

12.

Punjabi C, Tien V, Meng L, Deresinski S, Holubar M . Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019; . PMC: 6785705. DOI: 10.1093/ofid/ofz364. View

13.

Hilty M, Sendi P, Seiffert S, Droz S, Perreten V, Hujer A . Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?. Int J Antimicrob Agents. 2013; 41(3):236-49. PMC: 4018813. DOI: 10.1016/j.ijantimicag.2012.10.022. View

14.

Martin-Loeches I . Current Concepts in Community and Ventilator Associated Lower Respiratory Tract Infections in ICU Patients. Antibiotics (Basel). 2020; 9(7). PMC: 7399936. DOI: 10.3390/antibiotics9070380. View

15.

Johnson J, Porter S, Thuras P, Castanheira M . Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-30 (ST131-30), 2000 to 2009. Antimicrob Agents Chemother. 2017; 61(8). PMC: 5527581. DOI: 10.1128/AAC.00732-17. View

16.

Kaye K, Cosgrove S, Harris A, Eliopoulos G, Carmeli Y . Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001; 45(9):2628-30. PMC: 90703. DOI: 10.1128/AAC.45.9.2628-2630.2001. View

17.

Mizrahi A, Delerue T, Morel H, Le Monnier A, Carbonnelle E, Pilmis B . Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review. Int J Antimicrob Agents. 2019; 55(2):105834. DOI: 10.1016/j.ijantimicag.2019.10.015. View

18.

Lautenbach E, Metlay J, Bilker W, Edelstein P, Fishman N . Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005; 41(7):923-9. DOI: 10.1086/432940. View

19.

Shelenkov A, Mikhaylova Y, Yanushevich Y, Samoilov A, Petrova L, Fomina V . Molecular Typing, Characterization of Antimicrobial Resistance, Virulence Profiling and Analysis of Whole-Genome Sequence of Clinical Isolates. Antibiotics (Basel). 2020; 9(5). PMC: 7277670. DOI: 10.3390/antibiotics9050261. View

20.

Kadri S, Lai Y, Ricotta E, Strich J, Babiker A, Rhee C . External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infect Dis. 2019; 6(4):ofz110. PMC: 6441782. DOI: 10.1093/ofid/ofz110. View